Trade Tensions Weigh Heavily on 10 Stocks

4. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio fell by 13.37 percent on Monday to finish at $2.85 apiece, weighed by an overall market sentiment, with investors shunning news of increased sales from its ANKTIVA treatment.

According to the company, it saw increased sales momentum supporting a trend of increases month-on-month and quarter-on-quarter, with February sales volume growing by 67 percent over January.

It also said that sales for the past two months alone already exceeded the overall unit sales achieved in the fourth quarter of 2024.

In other news, IBRX saw net loss in the fourth quarter of 2024 narrowed by 75 percent to $59.18 million from $233 million in the same period a year earlier, while net loss for full-year 2024 shrunk by 29 percent to $413.6 million from $583.8 million in 2023.

The improved earnings was supported by higher revenues for both the quarter and full year, which soared by 5,333 percent to $7.5 billion from $139 million and by 2,270 percent to $14.7 billion from $622 million, respectively.